Senior Director, HEOR, Cell and Gene Therapy Pipeline Lead @ (August 2022 - February 2025)
Director, HEOR, Type 1 Diabetes Lead (Cell Therapy) @ (May 2021 - July 2022)
Senior Director HEOR @ (September 2020 - April 2021)
Director HEOR @ (July 2019 - September 2020)
Associate Director HEOR @ (October 2018 - June 2019)
Senior Manager HEOR @ (September 2017 - September 2018)
Senior Analyst HEOR @ (July 2016 - September 2017)
Post-doctoral PharmD Fellow HEOR @ (July 2015 - July 2016)
Scientist @ (July 2008 - July 2012)
Associate Scientist @ (April 2006 - July 2008)
Production Associate @ (January 2004 - September 2005)
Patrick Callahan Education
Massachusetts College of Pharmacy and Health Sciences
Doctor of Pharmacy (PharmD)
Northeastern University
Master of Science - MS
University of Massachusetts Amherst
Bachelor of Arts - BA
University of Massachusetts Amherst
Bachelor of Science - BS
Patrick Callahan Skills
Drug Discovery
Assay Development
In Vitro
Cell Culture
Oncology
Biotechnology
Pharmacology
ELISA
Cell
Cell Biology
Molecular Biology
Pharmacokinetics
Biomarkers
Drug Development
Immunology
Clinical Research
Cancer
Flow Cytometry
Western Blotting
Immunohistochemistry
Health Economics
Outcomes Research
Patient Reported Outcomes
Economic Modeling
Leadership
Patient Reported
Teaching
IRB
See 9+See Less
Microsoft Office
Protocol
Customer Service
Design
Project Management
Research
HEOR
Patrick Callahan Summary
Patrick Callahan, based in Pittsburgh, PA, US, is currently a Senior Director, HEOR and Evidence Generation, Gene Therapy at Encoded Therapeutics Inc.. Patrick Callahan brings experience from previous roles at Vertex Pharmaceuticals and Genesis Research. Patrick Callahan holds a Doctor of Pharmacy (PharmD) @ Massachusetts College of Pharmacy and Health Sciences. With a robust skill set that includes Drug Discovery, Assay Development, In Vitro, Cell Culture, Oncology and more. Patrick Callahan has 3 emails and 3 mobile phone numbers on RocketReach.
Looking for a different Patrick Callahan?
Find contact details for 700 million professionals.